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Objective To identify risk factors for Rhesus D (RhD)
immunisation in pregnancy, despite adequate antenatal and
postnatal anti-D prophylaxis in the previous pregnancy. To
generate evidence for improved primary prevention by extra
administration of anti-D Ig in the presence of a risk factor.
Design Case–control study.
Setting Nation-wide evaluation of the Dutch antenatal anti-
D-prophylaxis programme.
Population Cases: 42 RhD-immunised parae-1, recognised by
ﬁrst-trimester routine red cell antibody screening in their current
pregnancy, who received antenatal and postnatal anti-D Ig
prophylaxis (gifts of 1000 iu) in their ﬁrst pregnancy. Controls:
339 parae-1 without red cell antibodies.
Methods Data were collected via obstetric care workers and/or
personal interviews with women.
Main outcome measure Signiﬁcant risk factors for RhD
immunisation in multivariate analysis.
Results Independent risk factors were non-spontaneous delivery
(assisted vaginal delivery or caesarean section) (OR 2.23; 95%
CI:1.04–4.74), postmaturity (‡42 weeks of completed gestation:
OR 3.07; 95% CI:1.02–9.02), pregnancy-related red blood cell
transfusion (OR 3.51; 95% CI:0.97–12.7 and age (OR 0.89/year;
95% CI:0.80–0.98). In 43% of cases, none of the categorical risk
factors was present.
Conclusions In at least half of the failures of anti-D Ig
prophylaxis, a condition related to increased fetomaternal
haemorrhage (FMH) and/or insufﬁcient anti-D Ig levels was
observed. Hence, RhD immunisation may be further reduced by
strict compliance to guidelines concerning determination of FMH
and accordingly adjusted anti-D Ig prophylaxis, or by routine
administration of extra anti-D Ig after a non-spontaneous delivery
and/or a complicated or prolonged third stage of labour.
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Introduction
Haemolytic disease of the fetus and newborn (HDFN) has
long been a major speciﬁc cause of perinatal mortality and
morbidity.
1 In 1941, Levine elucidated the process of fetal
and neonatal red cell destruction because of maternal red cell
antibodies, a process he coined ‘immunisation’.
2 Rhesus D
(RhD) antibodies appeared to be responsible for most cases
of severe HDFN.
3,4. In the case of RhD immunisation, the
common sequence is a prior pregnancy with an RhD-positive
fetus, which induces fetomaternal haemorrhage (FMH)-
related immunisation and a subsequent pregnancy with
another RhD-positive fetus, which triggers manifest disease.
Administration of anti-D immunoglobulin (Ig) sup-
presses the immune response of an RhD-negative mother,
exposed to RhD-positive fetal cells; the precise mechanism
is still unclear.
5,6 Anti-D Ig supposedly induces rapid clear-
ance of RhD-positive fetal cells, interfering with the presen-
tation of the RhD blood group antigen by dendritic cells
and macrophages; additionally, it might be that RhD-
reactive B cells are suppressed in the production of RhD
antibodies.
6 Routine postnatal administration of anti-D Ig
signiﬁcantly prevents the occurrence of HDFN and has
been successfully introduced in developed countries since
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www.bjog.org General obstetrics1969. Additional guidelines advise administering anti-D
Ig in conditions prone to FMH, such as miscarriage,
termination of pregnancy, invasive prenatal diagnostic pro-
cedures, external version, caesarean section.
7–9 The com-
bined strategy of routine postnatal administration as part
of national prevention programmes and of additional anti-
D Ig in high-risk conditions during pregnancy and delivery
has substantially decreased RhD immunisation in all devel-
oped countries. A further decrease was observed in several
studies investigating routine antenatal administration of
anti-D Ig, primarily to prevent immunisation from unde-
tected FMHs during the last trimester of pregnancy.
10–12
But, even if postnatal and antenatal prophylaxis are com-
bined, 0.1–0.3% of women at risk still develop RhD anti-
bodies,
13,14 contributing to a signiﬁcant number of new
RhD immunisations and cases of HDFN. For example, 18
of the 34 new RhD immunisations in parae-1 in 2004 in
the Netherlands occurred despite adequate prophylaxis in
the previous pregnancy.
14 If preventable risk factors
contributing to remaining immunisation can be identiﬁed,
a further decrease of HDFN could be achieved. Studies
concerning remaining risk factors commonly apply the
Kleihauer–Betke test as outcome proxy for immunisation
risk; no study has so far identiﬁed the risk factors based on
actual RhD immunisation in the next pregnancy as primary
outcome. Existing studies using the Kleihauer proxy show
varying results and provide no evidence for a correlation
between large FMH and the incidence of events, accepted
as risk factors for FMH, for example, caesarean section.
15–19
Salim et al.
19 performed the largest prospective controlled
study on 313 women who underwent caesarean section and
253 women with a vaginal delivery, and did not ﬁnd any
evidence for a relation between the mode of delivery and the
rate of large FMH. Differences in the application of the
Kleihauer–Betke test (e.g. cut-off point for a positive test,
the interval between delivery and the Kleihauer–Betke test)
and/or a poor relation between the Kleihauer–Betke test and
RhD immunisation risk contribute to this lack of evidence.
The present case–control study aimed to detect risk fac-
tors for observed RhD immunisation as detected in the
next pregnancy, to optimise prevention programmes for
RhD immunisation.
Materials and methods
National prevention programme
The Dutch programme for prevention and detection of
RhD immunisation in pregnancy is free of charge. All
RhD-negative women who deliver an RhD-positive child
receive 200 lg (1000 iu) of anti-D Ig within 48 hours of
delivery. Antenatal anti-D prophylaxis has been introduced
since 1 July 1998. One dose of 200 lg anti-D Ig is adminis-
tered in the 30th week of pregnancy, which was until May
2008, restricted to RhD-negative women without a living
child, because of anti-D Ig scarcity.
An additional dose of anti-D Ig on top of routine anti-D
prophylaxis is advised after a miscarriage (>10 weeks of
completed gestation), after termination of pregnancy and
after invasive procedures or external version during preg-
nancy. A Kleihauer–Betke test for guiding of doses of anti-D
Ig is advised after abdominal trauma during pregnancy and
after twin delivery, caesarean section, fundal pressure or
surgical removal of the placenta.
8 All pregnant women are
screened for red cell antibodies in the ﬁrst trimester of preg-
nancy; RhD-negative women are screened again in the 30th
week.
20 The programme is monitored by an individual data
registry (demographic characteristics of the mother, parity,
RhD factor, screening results, antenatal and postnatal anti-D
Ig administration) at the National Vaccination Ofﬁces. The
coverage of the prevention programme is close to 100%.
21
Study design
We performed a case–control study. Cases were 42 RhD-
negative parae-1 with an RhD immunisation, newly
detected upon ﬁrst-trimester screening, who developed
RhD antibodies despite the documented administration of
adequate antenatal and postnatal prophylaxis during their
previous pregnancy and delivery. The cases were identiﬁed
in a nationwide study, covering 1999, 2002 and 2004,
which evaluated the effect of routine antenatal anti-D pro-
phylaxis. The total number of births (from 24 weeks
onwards) during these years was 391 000 (National Birth
Statistics). The prevalence of new RhD immunisations
upon ﬁrst-trimester screening in parae-1, despite antenatal
a ´nd postnatal anti-D-prophylaxis in the ﬁrst pregnancy,
was 0.31% (39/12 576). The denominator for this preva-
lence, including all RhD-negative parae-1 who delivered
their ﬁrst child after introduction of antenatal anti-
D-prophylaxis in the Netherlands, was calculated from
National Birth Statistics (calculation described elsewhere).
14
During the study period, 37 cases were identiﬁed who for
sure received antenatal and postnatal anti-D. These cases
were included in the current case–control study, as well as
ﬁve cases identiﬁed in 2000 and 2003, as we also collected
risk factor data about these cases. Parae-1 who had a nega-
tive ﬁrst-trimester screening test but had a positive screen-
ing at or after the 30th week screening, were not included,
to restrict our analysis to risk factors during the ﬁrst preg-
nancy and delivery only. We included a control group of
339 (RhD-positive and RhD-negative) parae-1 with a nega-
tive result of the ﬁrst-trimester red cell antibody screening,
to compare the prevalence of putative risk factors in the
case group with the population prevalence. The controls
were randomly selected by obstetric care workers between 1
September 2002 and 1 June 2003 in a nationwide evalua-
tion study of the non-RhD Red Blood Cell (RBC) antibody
Koelewijn et al.
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22 The controls
in this study were matched with the cases (pregnancies
with a non-RhD immunisation) for obstetric care worker
and gestational age and included around the 20th week of
pregnancy. The obstetric workers in primary care (mid-
wives and general practitioners) recruited three controls
and obstetricians (clinical care) recruited only one, because
of time constraints. From the 968 controls in this evalua-
tion study (the total population of pregnant women during
the inclusion period was ±150 000 according to National
Birth Statistics), we selected all parae-1 who delivered their
ﬁrst child from 15 September 1998 onwards, at a gesta-
tional age of at least 30 weeks (n = 339), implicating that
the 30th week of pregnancy was after the introduction of
the antenatal anti-D prophylaxis programme in the Nether-
lands. As exposure to potential risk factors is unrelated
to the RhD factor of the woman, data from both
RhD-positive and RhD-negative women could be used.
All controls gave informed consent for participation in
studies concerning pregnancy immunisation. The study was
approved by the relevant professional organisations (obste-
tricians, midwives, general practitioners, paediatricians,
clinical laboratories). Representatives of those organisations
monitored the study process. Registration data are legally
available for scientiﬁc research in the Netherlands. Primary
study data about the cases were retrieved from existing reg-
istries; these data were completed by additional routine
care data, obtained from the obstetric care workers. These
study procedures do not require individual consent under
Dutch law.
Data collection methods
After primary selection of cases via laboratory registries,
additional data were collected about potential risk factors
via the obstetric care worker, with a structured question-
naire, mainly in a telephone interview, from July 2004 until
April 2005. The source of the risk factor data was the med-
ical record of the previous pregnancy and the record of the
current pregnancy, which includes information about the
obstetric history. Potential risk factors were related to
increased FMH, decreased levels of anti-D Ig or altered
immune response (maternal weight, ethnicity and age,
paternal ethnicity, gender of the child, twin pregnancy,
invasive prenatal diagnostic procedures, external version,
postmaturity (‡42 weeks of completed gestation), mode of
delivery, surgical removal of the placenta, pregnancy-related
RBC transfusion). Similar data were collected from the
controls, via the obstetric care worker (40%) or from the
pregnant woman in a personal interview by phone by two
of the investigators, who were experienced interviewers
(60%) (JK, TV). It was not possible to collect valid data
about fundal pressure, as this procedure was not always
documented in the medical records, especially not in cases
with assisted vaginal delivery and women themselves were
not always sure whether fundal pressure was given or not.
Since ABO blood group incompatibility between mother
and fetus can protect against RhD immunisation,
23 we also
evaluated whether there was a difference in ABO blood
group distribution between cases and controls. The knowl-
edge about the presence of RhD antibodies theoretically
could have induced recall bias. We judge this to be unli-
kely, as the signiﬁcant risk factors are well deﬁned.
Data-analysis
First, univariate analysis of risk factors was performed
(Pearson’s chi-square test, Fisher’s exact test (n <5 ) o r
Student’s t-test, depending on the measurement level of the
variable). Next, multivariate logistic regression analysis was
performed. Univariate factors shown to be important
(P < 0.10) were offered stepwise to the model; models were
checked for interaction. In case of distorting collinearity
(two variables with overlap), we selected the variable most
causally connected to the outcome, rather than the one
with highest explanatory power. Finally, we estimated the
remnant risk for RhD immunisation in the next pregnancy
for all possible combinations of signiﬁcant risk factors by
multiplying the Odds ratio, predicted by the model, with
the baseline immunisation prevalence of 0.310% in women
without signiﬁcant risk factors and adequate antenatal and
postnatal prophylaxis
14 (supplemental data and calculations
available from the authors).
By design, controls under primary care in early pregnancy
(with a lower prevalence of potential risk factors such as for
example a previous caesarean section) were over-represented,
which could contribute to over-estimation of the effect of
potential risk factors. We therefore restored the proportion
of primary care pregnancies in the control group (298/
339 = 88%) to the population proportion for primiparae of
72%
24 by weighting the primary care controls with 0.35.
These weighted data were used in all analyses.
Missing values (<1%) were not substituted. Goodness of
ﬁt of the logistic regression models was assessed by the stan-
dard Hosmer and Lemeshow test. All statistical analyses were
performed in SPSS 11.0 (SPSS Inc., Chicago, IL, USA).
Results
Risk factors for RhD immunisation, univariate
analysis
As shown in Table 1, postmaturity (‡42 weeks of com-
pleted gestation), non-spontaneous delivery (assisted vagi-
nal delivery or caesarean section), pregnancy-related RBC
transfusion and the birth of twins, were found to be signiﬁ-
cant univariate risk factors for RhD immunisation in
parae-1 with RhD antibodies detected in ﬁrst-trimester
screening. Caesarean section and assisted vaginal delivery
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to increase power. In our view, this is justiﬁed because of
the same supposed underlying mechanism and the compa-
rable univariate ORs of 2.1 and 1.7 respectively. Unexpect-
edly, younger age at ﬁrst delivery was a signiﬁcant risk
factor for RhD immunisation (P = 0.02). We have no indi-
cations that this was an artefact of our study design, since
the mean age of the control group was comparable with
the mean age of primiparae in the Dutch population
according to published national registry data (29.1 years
from 2000 until 2005).
25 We did not observe a difference
in birth interval between the cases (2.57 year) and the con-
trol group (2.51 year) either.
A relatively high distribution volume of anti-D Ig pro-
phylaxis, as reﬂected by high body weight or body mass
index, did not emerge as a risk factor.
Before the introduction of anti-D Ig immunoprophylax-
is, ABO antagonism between mother and child was
observed to decrease the risk for immunisation.
23 No direct
information on ABO-incompatibility between mother and
ﬁrst child was available, but we did not observe an over-
representation of mothers with blood group A or AB in
the cases; hence, we did not observe any protective effect
of maternal blood group O or B. (Table 1). Invasive prena-
tal diagnostic procedures and external version in a previ-
ous pregnancy, as well as a miscarriage or termination of
pregnancy after the ﬁrst completed pregnancy and deliv-
ery—all risk factors for FMH where guidelines prescribe
additional anti-D Ig administration—did not emerge as
risk factor (Table 1). All but one abortions were spontane-
ous miscarriages; one termination of pregnancy was
observed in the case group of which the duration of preg-
nancy and administration of anti-D-prophylaxis were
unknown.
Non-Dutch ethnicity of the mother or father were not
risk factors for RhD immunisation in parae-1. It has previ-
ously been reported that male children are more frequently
affected by RhD immunisation,
26 but in our study, the sex
of the ﬁrst child did not signiﬁcantly inﬂuence the immu-
nisation risk although a slightly higher incidence of a prior
male child was observed in the cases (Table 1).
Risk factors for RhD immunisation, multivariate
analysis
From the multivariate analyses, postmaturity (OR 3.07).
caesarean section or assisted vaginal delivery (OR 2.23) and
age at ﬁrst delivery (0.89/year) emerged as signiﬁcant risk
factors for RhD immunisation; pregnancy-related RBC
transfusion was almost signiﬁcant (OR 3.51); see Table 2.
The risk factor ‘twins’ was, despite the P-value of 0.05 in the
univariate analysis, not offered to the multivariate models,
because the prevalence in the control group was 0%. We
could not establish any interaction between risk factors.
In 43% of the cases, none of the signiﬁcant categorical
multivariate risk factors such as non-spontaneous
delivery (caesarean section or vaginal assisted delivery),
Table 1. Univariate risk factors for newly detected RhD
immunisations in parae-1 with completed anti-D Ig prophylaxis
during ﬁrst pregnancy and delivery
Risk factors in 1st
pregnancy/delivery
Cases
(n = 42)
Controls
(n = 339*)
P-value*
General
Maternal blood group
A/AB (%)
40.5 43.2 0.76
Body mass index—mean (SD) 23.8 (4.5) 24.0 (4.5) 0.84
Body weight—mean
(SD) in kg
67.6 (11.5) 69.6 (13.3) 0.42
Body weight >75 kg (%) 21.9 23.8 0.82
Body weight >100 kg (%) 3.1 3.3 0.71
Maternal ethnicity
non-Dutch (%)
7.3 7.5 0.64
Previous pregnancy and delivery
Maternal age at delivery—
mean (SD) in years
27.9 (4.2) 29.4 (3.4) 0.02
Paternal ethnicity non-Dutch
(%)
10.8 8.7 0.45
Male child (%) 59.5 48.3 0.21
Twins (%) 4.8 0 0.05
Invasive prenatal diagnostic
procedures (%)
2.4 0.7 0.39
External version (%) 0 2.8 0.37
Postmaturity (‡42 weeks
of completed gestation) (%)
19.0 5.5 0.01
Non-spontaneous delivery (%) 47.6 29.3 0.03
Caesarean section (%) 23.8 13.0 0.09
Assisted vaginal delivery (%) 23.8 15.8 0.23
Surgical removal of
placenta (%)
6.3 4.7 0.50
Pregnancy-related RBC
transfusion (%)
14.3 3.4 0.02
Preceding interval 1st–2nd child
Abortion(s) (%) 11.9 13.0 0.85
*Weighted controls: n = 146; all P-values based on n = 146.
Table 2. Multivariate risk factors for newly detected RhD
immunisations in parae-1 with completed anti-D Ig prophylaxis
during ﬁrst pregnancy and delivery
OR 95% CI
Postmaturity (‡42 weeks of completed gestation) 3.07 1.02–9.20
Caesarean section or assisted vaginal delivery 2.23 1.04–4.74
Maternal age at delivery (years) 0.89 0.80–0.98
Pregnancy-related RBC transfusion 3.51 0.97–12.7
R
2 = 0.150.
Koelewijn et al.
1310 ª 2009 The Authors Journal compilation ª RCOG 2009 BJOG An International Journal of Obstetrics and Gynaecologypostmaturity and RBC transfusion were present (‘spontane-
ous’ cases), compared to in 65% of the controls.
To calculate the risk for RhD immunisation in the next
pregnancy of combinations of risk factors, we dichotomised
age at previous delivery in two groups: younger and older
than the mean age in the control group (29.35 years). The
calculated immunisation risk (point estimate) varied from
0.2% (95% CI: 0.005–0.33%) in women without risk fac-
tors to 2.0% (95% CI: 1.57–3.46%) if all signiﬁcant risk
factors are present (Table 3).
Discussion
Our study is the ﬁrst providing direct evidence about caus-
ative risk factors for veriﬁed RhD immunisation in the next
pregnancy, despite adequate antenatal and postnatal anti-D
prophylaxis, given as single doses of 1000 iu (200 lg). A
relatively young age at ﬁrst delivery, non-spontaneous
delivery (caesarean section or assisted vaginal delivery) and
postmaturity of the previous pregnancy emerged as inde-
pendent risk factors that signiﬁcantly contributed to the
development of RhD antibodies. Pregnancy-related RBC
transfusion, despite its lower conﬁdence limit of 0.97, can
most likely be added to this risk set. The expected risk fac-
tor of twins was established in the univariate analysis, but
could not be analysed in the multivariate analysis because
twins were missing in our control group.
A non-spontaneous delivery (caesarean section or assisted
vaginal delivery) can be considered as a risk factor for
increased FMH, exceeding the amount of fetal cells that can
be neutralised by a single gift of anti-D Ig of 1000 iu
(200 lg). Most national guidelines advise to quantify the
FMH by a Kleihauer–Betke test after caesarean section to
guide the dosage of postnatal anti-D Ig.
7–9 However, until
now there was no clear evidence for this policy. Several
cohort studies showed no correlation between assisted
delivery and the presence of FMH, but none of these studies
provided data about subsequent immunisation
15–19,27 Our
results suggest that, at least in the above mentioned studies,
the sensitivity and the speciﬁcity of the Kleihauer–Betke test
were apparently insufﬁcient in demonstrating increased
FMH after a non-spontaneous delivery. This can be explai-
ned in several ways. First, the application of the Kleihauer–
Betke test (e.g. the selected cut-off point for a positive test)
varied between the studies. Second, to detect risk factors
for a relatively rare condition as a (large) FMH, a cohort
study is not the most appropriate study design, because large
numbers of women with a potential risk factor have to be
included to achieve enough power. Third, one could argue
that the Kleihauer–Betke test misses some FMHs relevant for
immunisation. The Kleihauer–Betke test can be performed
manually with stained blood smears or using a ﬂow cytome-
try-based method and the technical merit and validation of
the used method may be of inﬂuence on test performance.
28
Furthermore, fetal blood loss into the maternal intraperito-
neal cavity, hence not detectable by the Kleihauer–Betke test,
might well lead to RhD immunisation.
The postmaturity risk factor might be explained by
insufﬁcient levels of preventive anti-D Ig, after a single gift
of 1000 iu (200 lg) in week 30 of pregnancy, in addition
to the obvious immunogenic effect of prolonged exposure
to fetal cells. Several studies showed undetectable levels of
anti-D Ig more than 12 weeks after administration, even
when 300 lg of anti-D Ig was administered in a single
gift;
29 therefore, anti-D Ig levels may drop too low if a
pregnancy exceeds 42 weeks.
30–32
RBC transfusion is a less obvious factor contributing to
RhD immunisation. Most likely, the RhD-negative RBCs
have been given in all cases, as false-negative typing of
donors is extremely rare.
33 The most likely explanation in
our view rests on spurious association: RBC transfusions
are usually given to women after complicated delivery or
Table 3. Model-based risk for RhD immunisation in next pregnancy with completed anti-D Ig prophylaxis in the previous pregnancy, according
to the presence of risk factors
Age at previous delivery
> 29.3 years
Age at previous delivery
< 29.3 years
Duration of
pregnancy
<42 weeks
Duration of
pregnancy
‡42 weeks
Duration of
pregnancy
<42 weeks
Duration of
pregnancy
‡42 weeks
Spontaneous delivery
No RBC transfusion 0.2% 0.6% 0.4% 1.0%
RBC transfusion 0.7% 1.3% 1.0% 1.6%
Assisted or surgical delivery
No RBC transfusion 0.4% 1.0% 0.7% 1.3%
RBC transfusion 1.1% 1.7% 1.4% 2.0%
Risk factors for RhD immunisation
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concomitant higher FMH risk. Alternatively, we can think
of transfusion-induced triggering of the immune system, in
general, stimulating the response to the fetal cells, which is
supported by the observation that two out of six transfused
women also had developed non-Rh antibodies [anti-K,
anti-Fy(a)], compared with none of the RhD immunised
women without a RBC transfusion (P = 0.017).
Finally, the independent effect of age at time of delivery
on the RhD immunisation risk is difﬁcult to explain. It is
known that elderly people have diminished immune
responses to vaccines and to solid organ transplanta-
tions,
34,35 but an effect of age in this healthy young group
of women leading to an increased immunisation risk, is
poorly understood. Theoretically, the effect could be caused
by indirect factors, not covered by our study, that are
related to maternal age and immunisation risk.
Our study on risk factors for manifest RhD immunisa-
tion, instead of on factors related to the immunisation path-
way (FMH), identiﬁed preventable risk factors and in our
view provides opportunities to decrease the incidence of
RhD immunisation. Assisted vaginal delivery and preg-
nancy-related RBC transfusion should be added to the set of
risk factors for RhD immunisation in the current guidelines.
In the presence of a risk factor, two policies are to be con-
sidered: administration of a standard extra dosage of anti-D
Ig or testing for FMH, followed by adjusted anti-D Ig pro-
phylaxis. Considering the ﬁrst policy, it is reassuring that
clinical conditions where standard additional anti-D Ig is
universally prescribed, such as spontaneous miscarriage, ter-
mination of pregnancy, invasive procedures during preg-
nancy and external version, did not emerge as a risk factor
in our analysis. However, it should be kept in mind that our
sample size was too small to establish a difference in infre-
quent risk factors such as invasive diagnostic procedures.
Whether the second policy will decrease the RhD immunisa-
tion rate cannot be concluded from our study. In none of
the cases of assisted or surgical delivery in our study, a
Kleihauer–Betke test was performed and it seems plausible
that some cases might have been prevented if this test had
been performed, followed by adjusted anti-D Ig administra-
tion. However, we have no data about the application of the
Kleihauer–Betke test and its relation to immunisation status
later. Another consideration is the practicability of such a
test-based approach of additional anti-D Ig administration.
The lack of testing we observed in our cases, even after a
caesarean section, is in contrast with the current Dutch gui-
delines, which suggest (rather than prescribe) a Kleihauer–
Betke test.
8 Replies to an e-mail questionnaire, without
reference to our observations, under half of all obstetric
partnerships in the Netherlands (response rate 70%),
showed that about 50% of them do not perform a Kleihau-
er–Betke test and administer the standard dosage anti-D Ig
after a caesarean section or after fundal pressure; after an
assisted vaginal delivery, >90% of the obstetricians do not
test and provide the standard dose of anti-D Ig (J.M. Koe-
lewijn, unpubl obs.). In view of this observation and of the
fact that not all hospital laboratories are experienced in the
performance and interpretation of the Kleihauer–Betke test,
routinely administration of extra anti-D Ig in the presence
of a risk factor might be considered.
Another option to minimise the risk for RhD immunisa-
tion may be proposed. Splitting of the single dose of 200 lg
or 300 lg (1000 or 1500 iu respectively) of anti-D Ig into
two gifts, in week 28 and in week 34 respectively, will theo-
retically have a cumulative effect on anti-D Ig plasma levels,
which might contribute to sufﬁcient levels of anti-D Ig in
postmature pregnancies, hence to a decreased immunisation
risk. As far as we know, this theoretical consideration is not
supported by research data. Furthermore, there is evidence
that compliance with a two-dose regimen is less than
ideal.
36,36,37 Thus, splitting of the dosage can in our view
not be recommended at this moment. Another option
would be an additional dose of anti-D Ig in week 40 or 41,
but there are no data to support the efﬁcacy of such a prac-
tice. The aforementioned measures will be important in
reducing the remaining incidence of RhD immunisation,
especially in a prevention programme with a relatively small
dose of anti-D Ig and in countries without routine antenatal
prophylaxis,. This would in our study have been applicable
in 57% of current failures. If all immunisations in the next
pregnancies after a non-spontaneous ﬁrst delivery and or
pregnancy-related RBC transfusion (one-third of all ﬁrst
deliveries) could be prevented by administration of a stan-
dard extra dose of anti-D Ig or by test-guided administra-
tion of extra anti-D Ig, the Number Needed to Treat would
be ±110, compared to ±20 for routine postnatal anti-D pro-
phylaxis and ±350 for routine antenatal anti-D prophy-
laxis.
14 However, 43% of the failures cannot be explained by
risk factors associated with an increased FMH and/or too
low levels of anti-D Ig. From the biological point of view,
variations in individual immune response and the inﬂuence
of age are intriguing topics, needing further research.
In conclusion, our risk factor analysis provides indisput-
able targets to reduce RhD immunisations and subsequent
HDFN at an apparently low practical and ﬁnancial price, at
least in the Netherlands.
Disclosure of interest
There are no conﬂict of interests.
Contribution to authorship
All authors participated in the study design, interpretation
of the data and in writing of the paper. J.M. Koelewijn and
T.G.M. Vrijkotte participated in data collection. J.M. Koe-
lewijn, T.G.M. Vrijkotte and G.J. Bonsel participated in
Koelewijn et al.
1312 ª 2009 The Authors Journal compilation ª RCOG 2009 BJOG An International Journal of Obstetrics and Gynaecologydata analysis. All authors have seen and approved the ﬁnal
version of the paper.
Details of ethics approval
The study proposal was judged by the Ethical Committee
of the Academic Medical Centre in Amsterdam. This Com-
mittee established that this study design did not require
formal approval of the Committee.
All controls gave informed consent. Registration data are
legally available for scientiﬁc research in the Netherlands.
Primary study data about the cases were retrieved from
existing registries; these data were completed by additional
routine care data, obtained from the obstetric care workers.
These study procedures do not require individual consent
under Dutch law.
Funding
The OPZI (detection and prevention of pregnancy immu-
nisation)-project, the nationwide evaluation of pregnancy
screening for RBC antibodies other than anti-D and of
antenatal anti-D-prophylaxis in the Netherlands, performed
by Sanquin Research and the Academic Medical Centre of
the University of Amsterdam, was ﬁnanced by the Health
Care Insurance Board.
Acknowledgements
The study was supported by the Dutch Health Care Insur-
ance Board. This organisation was not involved in the
study design, data analysis and interpretation and in the
writing of this article. We thank all obstetric care workers
who included cases and controls and provided data about.
Ms F. Winia and Ms. M. Vonk and midwifery-students,
whoparticipated in the identiﬁcation of cases and in the
data collection. The Royal Dutch Association of Midwives
(KNOV), the Dutch Society of Obstetrics and Gynaecology
(NVOG), the National Society of General Practitioners
(LHV), the Dutch Society for Clinical Chemistry (NVKC),
the Dutch Society of Pediatrics (NVK), provided generous
and unconditional support throughout this study. Cases
were identiﬁed by Sanquin Diagnostic Services (Amster-
dam) and the Special Institute for Blood group Investiga-
tions (BIBO, Groningen); Drs M.A.M. Overbeeke and
C.A.M. Hazenberg are acknowledged for making data of
their laboratory registries available for the study.j
References
1 Bowman JM. RhD hemolytic disease of the newborn. N Engl J Med
1998;339:1775–7.
2 Levine P, Burnham L, Katzin EM, Vogel P. The role of iso-immuniza-
tion in the pathogenesis of erythroblastosis fetalis. JAMA
1941;113:126–7.
3 Mollison PL, Engelfriet CP, Contreras M. Haemolytic disease of the
fetus and the newborn. In: Mollison PL, Engelfriet CP, Contreras M,
editors. Blood Transfusion in Clinical Medicine, 10th edn. Oxford:
Blackwell Science; 1997. pp. 390–424.
4 Daniels G. Blood group antibodies in haemolytic disease of the fetus
and newborn. In: Hadly A, Soothill P, editors. Alloimmune Disorders
of Pregnancy. Cambridge: University Press; 2002. pp. 21–40.
5 Urbaniak SJ, Greiss MA. RhD haemolytic disease of the fetus and
the newborn. Blood Rev 2000;14:44–61.
6 Kumpel BM. On the immunologic basis of Rh immune globulin (anti-
D) prophylaxis. Transfusion 2006;46:1652–6.
7 NICE. Routine Antenatal Anti-D Prophylaxis for Women who are
Rhesus D Negative. NICE Technology Appraisal Guidance 156.
London, UK: National Institute for Health and Clinical Excellence,
2008.
8 Vandenbussche FPHA, Klumper FJ. [Red cell immunisation and preg-
nancy]. Dutch Society of Obstetrics and Gynaecoly 2002; clinical
guideline [Dutch].
9 American College of Obstetricans and Gynecologists. ACOG practice
bulletin. Prevention of Rh D alloimmunization. Number 4, May 1999
(replaces educational bulletin Number 147, October 1990). Clinical
management guidelines for obstetrician-gynecologists. American College
of Obstetrics and Gynecology. Int J Gynaecol Obstet 1999;66:63–70.
10 Crowther CA, Keirse MJ. Anti-D administration in pregnancy for pre-
venting rhesus alloimmunisation. Cochrane Database Syst Rev
2000:CD000020.
11 Chilcott J, Lloyd JM, Wight J, Forman K, Wray J, Beverley C, et al. A
review of the clinical effectiveness and cost-effectiveness of routine
anti-D prophylaxis for pregnant women who are rhesus-negative.
Health Technol Assess 2003;7:4.
12 Jones ML, Wray J, Wight J, Chilcott J, Forman K, Tappenden P,
et al. A review of the clinical effectiveness of routine antenatal anti-
D prophylaxis for rhesus-negative women who are pregnant. BJOG
2004;111:892–902.
13 Engelfriet CP, Reesink HW, Judd WJ, Ulander VM, Kuosmanen M,
Koskinen S, et al. Current status of immunoprophylaxis with anti-D
immunoglobin. Vox Sang 2003;85:328–37.
14 Koelewijn JM, de Haas M, Vrijkotte TG, Bonsel GJ, Van der Schoot
CE. One single dose of 200 microg of antenatal RhIG halves the risk
of anti-D immunization and hemolytic disease of the fetus and new-
born in the next pregnancy. Transfusion 2008;48:1721–9.
15 Ness PM, Baldwin ML, Niebyl JR. Clinical high-risk designation does
not predict excess fetal-maternal hemorrhage. Am J Obstet Gynecol
1987;156:154–8.
16 Sebring ES, Polesky HF. Fetomaternal hemorrhage: incidence, risk
factors, time of occurrence, and clinical effects. Transfusion 1990;
30:344–57.
17 Feldman N, Skoll A, Sibai B. The incidence of signiﬁcant fetomater-
nal hemorrhage in patients undergoing cesarean section. Am J
Obstet Gynecol 1990;163:855–8.
18 David M, Smidt J, Chen FC, Stein U, Dudenhausen JW. Risk factors
for fetal-to-maternal transfusion in Rh D-negative women—results
of a prospective study on 942 pregnant women. J Perinat Med
2004;32:254–7.
19 Salim R, Ben Shlomo I, Nachum Z, Mader R, Shalev E. The incidence
of large fetomaternal hemorrhage and the Kleihauer–Betke test.
Obstet Gynecol 2005;105:1039–44.
20 Health Care Insurance Board. Blood Testing in Pregnancy. Pregnancy
Immunisation, Hepatitis B and Lues. The Hague: Health Care Insur-
ance Board. National Health Inspection, 1998. [Dutch].
21 Van der Ploeg CPB, Anthony S, Rijpsta A, Verkerk PH. [Process Mon-
itoring Pre- and Postnatal Screenings 2003]. Leiden, the Netherlands:
TNO Quality of Life, 2006. [Dutch].
22 Koelewijn JM, Vrijkotte TG, Van der Schoot CE, Bonsel GJ, de Haas
M. Effect of screening for red cell antibodies, other than anti-D, to
Risk factors for RhD immunisation
ª 2009 The Authors Journal compilation ª RCOG 2009 BJOG An International Journal of Obstetrics and Gynaecology 1313detect hemolytic disease of the fetus and newborn: a population
study in the Netherlands. Transfusion 2008;48:941–52.
23 Murray S, Knox EG, Walker W. Rhesus haemolytic disease of the
newborn and the ABO groups. Vox Sang 1965;10:6–31.
24 Bais JMJ. Risk selection and detection: a critical appraisal of the
Dutch obstetric system. Thesis, Amsterdam: University of Amster-
dam, 2004, 25 pp.
25 [http://statline.cbs.nl/StatWeb/publication/?DM-SLNL&PA=37201&D1=
0,7-22&D2=5-16&D3=(l-5)-l&VW=T]. Accessed 19 August 2008.
26 Ulm B, Svolba G, Ulm MR, Bernaschek G, Panzer S. Male fetuses are
particularly affected by maternal alloimmunization to D antigen.
Transfusion 1999;39:169–73.
27 Mahboob U, Mazhar SB. Role of Kleihauer test in Rhesus negative
pregnancy. J Coll Physicians Surg Pak 2006;16:120–3.
28 Pelikan DM, Scherjon SA, Mesker WE, Groot-Swings GM, Brouwer-
Mandema GG, Tanke HJ, et al. Quantiﬁcation of fetomaternal
hemorrhage: a comparative study of the manual and automated
microscopic Kleihauer–Betke tests and ﬂow cytometry in clinical
samples. Am J Obstet Gynecol 2004;191:551–7.
29 Bowman JM, Pollock JM. Antenatal prophylaxis of Rh isoimmuniza-
tion: 28-weeks’-gestation service program. Can Med Assoc J
1978;118:627–30.
30 Kennedy MS, McNanie J, Waheed A. Detection of anti-D following
antepartum injections of Rh immune globulin. Immunohematology
1998;14:138–40.
31 Rudensky B, Mazaki E, Na’amad M, Samueloff A. Lack of anti-D in
women at birth following antepartum immune globulin prophylaxis.
Eur J Obstet Gynecol Reprod Biol 2003;107:45–6.
32 MacKenzie IZ, Roseman F, Findlay J, Thompson K, Jackson E, Scott
J, et al. The kinetics of routine antenatal prophylactic intramuscular
injections of polyclonal anti-D immunoglobulin. BJOG 2006;113:
97–101.
33 Denomme GA, Wagner FF, Fernandes BJ, Li W, Flegel WA. Partial D,
weak D types, and novel RHD alleles among 33,864 multiethnic
patients: implications for anti-D alloimmunization and prevention.
Transfusion 2005;45:1554–60.
34 Goodwin K, Viboud C, Simonsen L. Antibody response to inﬂuenza
vaccination in the elderly: a quantitative review. Vaccine
2006;24:1159–69.
35 Martins PN, Pratschke J, Pascher A, Fritsche L, Frei U, Neuhaus P,
et al. Age and immune response in organ transplantation. Trans-
plantation 2005;79:127–32.
36 MacKenzie I. Antenatal anti-D prophylaxis: one dose or two? BJM
2004;12:13–4.
37 MacKenzie IZ, Findlay J, Thompson K, Roseman F. Compliance with
routine antenatal rhesus D prophylaxis and the impact on sensitisa-
tions: observations over 14 years. BJOG 2006;113:839–43.
Koelewijn et al.
1314 ª 2009 The Authors Journal compilation ª RCOG 2009 BJOG An International Journal of Obstetrics and Gynaecology